相关临床试验
2
2 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
进行中（未招募）
1
50.0%
尚未招募
1
50.0%
暂无批准数据
- ALX Oncology's evorpacept combined with rituximab and lenalidomide achieved a 92% complete response rate in previously untreated indolent non-Hodgkin lymphoma patients, nearly doubling the historical 50% rate for standard therapy alone. - The Phase 2 investigator-sponsored trial enrolled 24 patients and demonstrated 100% overall response rate with well-tolerated safety profile in the frontline treatment setting. - One-year progression-free survival reached 91% and overall survival was 100%, supporting evorpacept's potential as a cornerstone immuno-oncology therapy targeting CD47. - The combination represents a promising non-chemotherapy regimen for patients with high tumor burden indolent B-cell lymphomas, with results presented at ASH 2025.
- Over 80 CD47 inhibitor drugs are currently in clinical trials across Phase I to Phase III stages, targeting both hematologic malignancies and solid tumors. - The first CD47 inhibitor drug approval is projected by 2028, with leading companies including Gilead Sciences, ALX Oncology, and I-Mab Biopharma driving innovation. - CD47 represents a promising "don't eat me" immune checkpoint target for cancer treatment, particularly for patients who don't respond to PD-1/PD-L1 inhibitors. - Future development focuses on bispecific antibodies, combination therapies, and biomarker-guided personalized treatment strategies to minimize toxicities while maximizing efficacy.
- Revolution Medicines has appointed Alan Sandler, M.D. as chief development officer to lead development of RAS(ON) inhibitors for RAS-addicted cancers. - The company also named regional general managers Alicia Gardner for the U.S. and Gerwin Winter for Europe to prepare for potential commercial launches. - Dr. Sandler brings extensive oncology drug development experience from ALX Oncology, Mirati Therapeutics, and Genentech to advance the company's clinical-stage pipeline. - The leadership additions support Revolution Medicines' preparation for potential approvals of daraxonrasib and other RAS-targeted therapies.
- ALX Oncology has appointed Dr. Barbara Klencke as Interim Chief Medical Officer, replacing Dr. Alan Sandler who will return to the company's Board of Directors. - Dr. Klencke brings over 30 years of experience in oncology drug development, including leadership roles at Sierra Oncology, Onyx Pharmaceuticals, and Genentech. - The appointment aims to accelerate development of ALX Oncology's pipeline, including evorpacept, a CD47 blocker in multiple clinical trials, and ALX2004, an EGFR-targeted antibody-drug conjugate that entered Phase 1 trials in August 2025. - Dr. Klencke previously served on ALX Oncology's Board of Directors since January 2025 and has witnessed the progress of both clinical programs firsthand.
- Pfizer has terminated a Phase II trial of maplirpacept in diffuse large B-cell lymphoma after enrolling only six patients since August 2023 due to recruitment difficulties. - The decision was not based on safety or efficacy concerns, according to the company's statement to federal clinical trials database. - This setback adds to mounting challenges for Pfizer's $2.26 billion Trillium acquisition and the broader CD47-targeting therapeutic space. - Pfizer continues to study maplirpacept in other blood cancers including multiple myeloma, with ongoing trials still recruiting patients.
• ALX Oncology reported that its CD47-blocking agent in combination with Merck's Keytruda (pembrolizumab) failed to meet primary endpoints in two separate Phase II clinical trials. • The combination therapy was being evaluated in patients with head and neck squamous cell carcinoma and non-small cell lung cancer, representing a setback for the emerging CD47 inhibitor class. • This failure adds to mounting challenges in the CD47 inhibitor space, which has seen several clinical disappointments despite the target's promising role in cancer immune evasion mechanisms.
- ALX Oncology announced that evorpacept combined with Keytruda (pembrolizumab), with or without chemotherapy, failed to meet primary endpoints in two Phase 2 trials for head and neck squamous cell carcinoma. - Despite showing a manageable safety profile, the company will discontinue pursuing this specific combination for HNSCC treatment, instead focusing on evorpacept's more promising combinations with anti-cancer antibodies in other tumor types. - Evorpacept, a CD47-blocker designed to help the immune system target cancer cells, will continue development in multiple clinical trials for breast cancer, colorectal cancer, non-Hodgkin lymphoma, and multiple myeloma.
- ALX Oncology announces initiation of two new randomized Phase II clinical trials targeting breast cancer and colorectal cancer, expanding their solid tumor portfolio. - Jefferies analyst Michael Yee upgrades ALX Oncology to Buy rating with price target increase to $3, citing favorable risk/reward profile and upcoming catalysts. - Company's strategic expansion into major solid tumor indications positions it for potential significant market value growth, with key data expected in 2026.
• The ASPEN-06 Phase 2 trial demonstrated a 41.3% overall response rate (ORR) with evorpacept plus trastuzumab, ramucirumab, and paclitaxel (ETRP) in previously treated HER2-positive gastric cancer patients. • Patients with confirmed HER2-positive tumors via fresh biopsy or ctDNA showed a 48.9% ORR and a median duration of response of 15.7 months with the evorpacept combination. • Evorpacept plus TRP was generally well-tolerated, with adverse events consistent with the control group, suggesting a manageable safety profile in this patient population. • The FDA has granted Fast Track designation to evorpacept for second-line treatment of HER2-positive gastric or gastroesophageal junction carcinoma, highlighting its potential clinical significance.
- ALX Oncology's ASPEN-06 Phase 2 trial evaluates evorpacept, a CD47-blocker, in HER2-positive advanced gastric cancer patients who have been previously treated. - Updated data from the ASPEN-06 trial were presented at the 2025 ASCO Gastrointestinal Cancers Symposium (ASCO GI). - The virtual event hosted by ALX Oncology on January 23, reviewed the ASPEN-06 data, focusing on evorpacept's potential in immuno-oncology. - The ASPEN-06 trial is a phase 2/3 study of evorpacept in patients with HER2-overexpressing gastric/gastroesophageal cancer.
